Cell-surface and cytokine biomarkers in autoimmune and inflammatory diseases

Drug Discovery Today

Volumn 11, Issue 7-8, 2006, Pages 342-347

  O'Hara Jr , Richard M ^a   Benoit, Stephen E ^a   Groves, Christopher J ^a   Collins, Mary ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIMALARIAL AGENT; ANTINUCLEAR ANTIBODY; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCINEURIN INHIBITOR; CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; CELL ANTIBODY; CELL SURFACE MARKER; CELL SURFACE RECEPTOR; CORTICOSTEROID; CYTOKINE; CYTOKINE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN M ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 8; METHOTREXATE; METHYLPREDNISOLONE; RAPAMYCIN; RITUXIMAB; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG; VASCULOTROPIN;

AUTOIMMUNE DISEASE; B LYMPHOCYTE; CARDIAC GRAFT REJECTION; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; DRUG MECHANISM; DRUG RESPONSE; GENETIC SCREENING; GRAFT RECIPIENT; HEART GRAFT; HUMAN; HYPOTENSION; IMMUNOPATHOGENESIS; INFLAMMATORY DISEASE; LABORATORY TEST; MULTIPLE SCLEROSIS; OSTEOARTHRITIS; REGULATORY T LYMPHOCYTE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TARGET CELL; TREATMENT RESPONSE;

ANTI-INFLAMMATORY AGENTS; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; BIOLOGICAL MARKERS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; CYTOKINES; HUMANS; INFLAMMATION; RECEPTORS, CELL SURFACE; T-LYMPHOCYTES;

EID: 33645859323     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2006.02.009     Document Type: Review

References (64)

1. DiMasi J.A. Risks in new development: approval success rates for investigational drugs. Clin. Pharmacol. Ther. 69 (2001) 297-307
2. Lesko L.J., and Atkinson Jr. A.J. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu. Rev. Pharmacol. Toxicol. 41 (2001) 347-366
3. Maini R.N., and Taylor P.C. Anti-cytokine therapy in rheumatoid arthritis. Annu. Rev. Med. 51 (2000) 207-229
4. Lipsky P.E. Integrating biologic therapy into the comprehensive care of patients with rheumatoid arthritis. J. Rheumatol. Suppl. 72 (2005) 54-57
5. Bombardier C., et al. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum. 35 (1992) 630-640
6. Arnett F.C., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31 (1988) 315-324
7. Renaudineau Y., et al. Rheumatoid factor on a daily basis. Autoimmunity 38 (2005) 11-16
8. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 (1983) 1444-1452
9. Wilke W.S., and Clough J.D. Therapy for rheumatoid arthritis: combinations of disease-modifying drugs and new paradigms of treatment. Semin. Arthritis Rheum. 21 Suppl. (1991) 21-34
10. Lipsky P.E. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat. Immunol. 2 (2001) 764-766
11. Spronk P.E., et al. Anti-DNA antibodies as early predictor for disease exacerbations in SLE: guideline for treatment?. Clin. Rev. Allergy Immunol. 16 (1998) 211-218
12. Esdaile J.M., et al. Routine immunologic tests in systemic lupus erythematosus: is there a need for more studies?. J. Rheumatol. 23 (1996) 1891-1896
13. Esdaile J.M., et al. Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus: why some tests fail. Arthritis Rheum. 39 (1996) 370-378
14. Schiffenbauer J., et al. Biomarkers, surrogate markers and design of clinical trials of new therapies for systemic lupus erythematosus. Arthritis Rheum. 50 (2004) 2415-2422
15. VanGool S.W., et al. CD8 CD86 and CD40 provide accessory signals in a multiple step T cell activation model. Immunol. Rev. 153 (1996) 47-83
16. Bijl M., et al. Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus. Ann. Rheum. Dis. 60 (2001) 523-526
17. Jacobi A.M., et al. Correlation between circulating CD27 high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 48 (2003) 1332-1342
18. Edwards J.C.W., et al. B lymphocyte depletion in rheumatoid arthritis: targeting of CD20. Curr. Dir. Autoimmun. 8 (2005) 175-192
19. Di Gaetano N., et al. Complement activation determines the therapeutic activity of rituximab in vivo. J. Immunol. 171 (2003) 1581-1587
20. Eisenbarth G.S. Type I diabetes: molecular, cellular and clinical immunology. Adv. Exp. Med. Biol. 552 (2004) 306-310
21. Pietropaolo M., and Eisenbarth G.S. Autoantibodies in human diabetes. Curr. Dir. Autoimmun. 4 (2001) 252-282
22. Sospedra M., and Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 23 (2005) 683-747
23. Fox E.J. Immunopathology of multiple sclerosis. Neurology 63 12 Suppl 6 (2004) S3-S7
24. Bisikirska B.C., and Herold K.C. Use of anti-CD3 monoclonal antibody to induce immune regulation in type I diabetes. Ann. N. Y. Acad. Sci. 1037 (2004) 1-9
25. von Herrath M.G. Pathogenesis of type I diabetes: a viewpoint. Adv. Exp. Med. Biol. 552 (2004) 317-321
26. Goronzy J.J., and Weyand C.M. T-cell regulation in rheumatoid arthritis. Curr. Opin. Rheumatol. 16 (2004) 212-217
27. Kremer J.M., et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve month results of a phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 52 (2005) 2263-2271
28. Chatzimanolis N., et al. CD45RA + ICAM3 + lymphocytes in interferon-β1b treated and untreated patients with relapsing-remitting multiple sclerosis. Acta Neurol. Scand. 110 (2004) 377-385
29. Kraus J., et al. CD45RA + ICAM-3 + lymphocytes in cerebrospinal fluid and blood as markers of disease activity in patents with multiple sclerosis. Acta Neurol. Scand 102 (2000) 26-32
30. Yazdany J., and Davis J. The role of CD40 ligand in systemic lupus erythematosus. Lupus 13 (2004) 377-380
31. Koshy M., et al. Increased expression of CD40 ligand on systemic. lupus erythematosus. J. Clin. Invest. 98 (1996) 826-837
32. Desai-Mehta A., et al. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J. Clin. Invest. 97 (1996) 2063-2073
33. Vakkalanka R.K., et al. Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera. Arthritis Rheum. 42 (1999) 871-877
34. Kato K., et al. The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J. Clin. Invest. 104 (1999) 947-955
35. Devi B.S., et al. Peripheral blood lymphocytes in SLE - hyperexpression of CD154 on T and B lymphocytes and increased number of double negative T cells. J. Autoimmun. 11 (1998) 471-475
36. Kawai T., et al. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat. Med. 6 (2000) 114
37. Wilson S.B., et al. Multiple differences in gene expression in regulatory Vα24JαQ T cells from identical twins discordant for type I diabetes. Proc. Natl. Acad. Sci. U. S. A 97 (2000) 741-746
38. Wang H.-Y., et al. Immune parameters associated with early treatment effects of high-dose intravenous methylprednisolone in multiple sclerosis. J. Neurol. Sci. 216 (2003) 61-66
39. Sakaguchi S., et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155 (1995) 1151-1164
40. Fontenot J.D., and Rudensky A.Y. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat. Immunol. 6 (2005) 331-337
41. Baan C.C., et al. Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells. Transplantation 80 (2005) 110-117
42. Ehrenstein M.R., et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF therapy. J. Exp. Med. 200 (2004) 277-285
43. Rosengren S., et al. Measurement of inflammatory biomarkers in synovial tissue extracts by enzyme-linked immunosorbent assay. Clin. Diagn. Lab. Immunol. 10 (2003) 1002-1010
44. Ballara S., et al. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum. 44 (2001) 2055-2064
45. Paleolog E.M., et al. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum. 41 (1998) 1258-1265
46. Nishimoto N., et al. Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann. Rheum. Dis. 59 Suppl. I (2000) i21-i27
47. Nakahara H., et al. Anti-interleukin 6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum. 48 (2003) 1521-1529
48. Baechler E.C., et al. The emerging role of interferon in human systemic lupus erythematosus. Curr. Opin. Immunol. 16 (2004) 801-807
49. Baechler E.C., et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. U. S. A 100 (2003) 2610-2615
50. Bennett L., et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197 (2003) 711-723
51. Kirou K.A., et al. Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum. 50 (2004) 3958-3967
52. Kotzin B.L., et al. Use of soluble peptide-DR4 tetramers to detect synovial T cells specific for cartilage antigens in patients with rheumatoid arthritis. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 291-296
53. Reijonen H., et al. Detection of CD4 + autoreactive T cells in T1D using HLA class II tetramers. Ann. N. Y. Acad. Sci. 1005 (2003) 82-87
54. Dyment D.A., et al. Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistance. Hum. Mol. Genet. 14 (2005) 2019-2026
55. Chow S., et al. Measurement of MAP kinase activation by flow cytometry using phospho-specific antibodies to MEK and ERK: potential for pharmacodynamic monitoring of signal transduction inhibitors. Cytometry 46 (2001) 72-78
56. Schubert L.A., et al. The human gp39 promoter. Two distinct nuclear factors of activated T cell protein-binding elements contribute independently to transcriptional activation. J. Biol. Chem. 270 (1995) 29624-29627
57. Sorensen T.L., and Sellebjerg F. Selective suppression of chemokine receptor CXCR3 expression by interferon-beta1a in multiple sclerosis. Mult. Scler. 8 (2002) 104-107
58. Leandro M.J., et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 46 (2002) 2673-2677
59. Thatayatikom A., and White A.J. Rituximab: a promising therapy in systemic lupus erythematosus. Autoimmun. Rev. 5 (2006) 18-24
60. Pachner A.R., et al. The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies. J. Neuroimmunol. 166 (2005) 180-188
61. Batliwalla F.M., et al. Peripheral blood gene expression profiling in rheumatoid arthritis. Genes Immun. 6 (2005) 388-397
62. Bitsch A., et al. Interferon beta-1b modulates serum sVCAM-1 levels in primary progressive multiple sclerosis. Acta Neurol. Scand. 110 (2004) 386-392
63. Washington R., et al. Expression of immunologically relevant endothelial cell activation antigens on isolated central nervous system microvessels from patients with multiple sclerosis. Ann. Neurol. 35 (1994) 89-97
64. Rieckmann P., et al. Soluble forms of intercellular adhesion molecule-1 (ICAM-1) block lymphocyte attachment to cerebral endothelial cells. J. Neuroimmunol. 60 (1995) 9-15